id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
19104709_1 | IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"recurrence of Graves' disease\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"IFNalpha\", \"ten years after thyroidectomy\"]], \"start\": [[0, 47]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"chronic viral hepatitis C\"]], \"start\": [[80]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"IFNalpha\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
15795553_2 | Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Risperidone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Risperidone\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"respiratory dyskinesia\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
17556909_2 | Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Paralytic ileus\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bortezomib treatment\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bortezomib\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11918514_4 | Severe serotonin syndrome induced by mirtazapine monotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced by\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"mirtazapine monotherapy\"]], \"start\": [[37]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"mirtazapine\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
21712512_6 | Three days after starting fluconazole, she developed polyuria and polydipsia and was found to have severe hyperglycemia, which led to the diagnosis of Cushing syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[43]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Three days after starting fluconazole\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"fluconazole\"]], \"start\": [[26]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"Three days\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"polyuria and polydipsia and was found to have severe hyperglycemia, which led to the diagnosis of Cushing syndrome\"]], \"start\": [[53]], \"entity_id\": [\"T10\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[99]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
10566542_1 | Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"hypocalcemic tetany\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fleet phospho-soda\"], [\"alendronate sodium\"]], \"start\": [[44], [95]], \"entity_id\": [\"T6\", \"T7\"], \"Drug\": {\"text\": [[\"fleet phospho-soda\"], [\"alendronate sodium\"]], \"start\": [[44], [95]], \"entity_id\": [\"T10\", \"T9\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
7854541_3 | Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[169]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"leukoencephalopathy\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"levamisole\"]], \"start\": [[195]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"levamisole\"]], \"start\": [[195]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[155]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
10589077_6 | We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[152]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"in five patients with thalassemia intermedia\"]], \"start\": [[107]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"five\"]], \"start\": [[110]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"HU alone or in combination with SPB\"]], \"start\": [[165]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"HU\"], [\"SPB\"]], \"start\": [[165], [197]], \"entity_id\": [\"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"thalassemia intermedia\"]], \"start\": [[129]], \"entity_id\": [\"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[180]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"HU\"], [\"SPB\"]], \"start\": [[165], [197]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"increases in total Hb and decreased transfusion needs\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19299370_1 | According to the Naranjo et al. adverse-reaction probability scale, enoxaparin was the probable cause of hepatotoxicity in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[96]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"enoxaparin\"]], \"start\": [[68]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[105]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[123]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[87]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
11788010_5 | This is the first reported case of hepatolithiasis during octreotide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"hepatolithiasis\"]], \"start\": [[35]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"octreotide\"]], \"start\": [[58]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"octreotide\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2781955_2 | Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis (AIT)\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"Treatment\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"thionamide, lithium or radioactive iodine\"]], \"start\": [[58]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"amiodarone-induced thyrotoxicosis (AIT)\"]], \"start\": [[13]], \"entity_id\": [\"T11\"]}}, \"Negated\": {\"text\": [[\"ineffective\"]], \"start\": [[103]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
2292051_2 | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy\"]], \"start\": [[145]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cis-diamine-dichloroplatinum II\"]], \"start\": [[145]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[196]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"Six patients with no previous signs or symptoms suggestive of coronary artery disease\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"Six\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute coronary ischemia/infarction\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
10891991_6 | RESULTS: Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Replacing valproate with lamotrigine\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"lamotrigine\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"a decrease in serum testosterone concentrations\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"all 3 women\"]], \"start\": [[109]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[113]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[115]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
6744146_1 | A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a small-bowel obstruction due to Amphojel concretions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[127]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"septic shock\"], [\"acute renal failure\"]], \"start\": [[59], [76]], \"entity_id\": [\"T7\", \"T1\"]}, \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"small-bowel obstruction\", \"concretions\"]], \"start\": [[103, 143]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Amphojel\"]], \"start\": [[134]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Amphojel\"]], \"start\": [[134]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
1879988_3 | After the first oral dose of propranolol, syncope developed together with atrioventricular block. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"oral dose of propranolol\"]], \"start\": [[16]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"oral\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"propranolol\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"syncope\", \"atrioventricular block\"]], \"start\": [[42, 74]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19764104_2 | Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Sorafenib\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Sorafenib\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"hepatocellular carcinoma\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"an advanced hepatocellular carcinoma patient\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"tumor lysis syndrome\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10660641_9 | The symptoms did not recur during the 36 months of itraconazole treatment after discharge, and it was concluded that ITCZ was effective for A. flavus hypertrophic pachymeningitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"effective\"]], \"start\": [[126]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"The symptoms did not recur\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"the 36 months of itraconazole treatment after discharge\"]], \"start\": [[34]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"A. flavus hypertrophic pachymeningitis\"]], \"start\": [[140]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"36 months\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[51]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
14679124_3 | A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"provides\"]], \"start\": [[146]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"the concomitant or the sequential addition of tamoxifen to chemotherapy\"]], \"start\": [[74]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[120]], \"entity_id\": [\"T13\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[133]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[210]], \"entity_id\": [\"T15\"]}}, \"Subject\": {\"text\": [[\"postmenopausal patients\"]], \"start\": [[227]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"postmenopausal\"]], \"start\": [[227]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"improved clinical benefit in the adjuvant treatment\"]], \"start\": [[155]], \"entity_id\": [\"T1\"]}, \"Speculated\": {\"text\": [[\"assess\"]], \"start\": [[59]], \"entity_id\": [\"T2\"], \"value\": true}}"
}
]
}
] |
11328247_2 | Increased libido in a woman treated with fluvoxamine: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Increased libido\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2935070_3 | In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[32]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"acute interstitial nephritis with renal failure and exfoliative dermatitis\"]], \"start\": [[50]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"ampicillin therapy\"]], \"start\": [[135]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[135]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[50]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
21417793_10 | Severe symptoms associated with serotonin toxicity were shown to be uncommon in patients receiving linezolid and selected serotonin reuptake inhibitors. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"linezolid and selected serotonin reuptake inhibitors\"]], \"start\": [[99]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"serotonin\"], [\"linezolid\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[32], [99], [122]], \"entity_id\": [\"T12\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[109]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[99], [122]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[80]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"Severe symptoms associated with serotonin toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Severity\": {\"text\": [[\"Severe\"], [\"uncommon\"]], \"start\": [[0], [68]], \"entity_id\": [\"T11\", \"T14\"], \"value\": \"High\"}}"
}
]
}
] |
10099659_9 | We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[29]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"side effects\"]], \"start\": [[16]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit\"]], \"start\": [[42]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"mucositis\"], [\"desquamating dermatitis\"], [\"myelosuppression\"], [\"neurologic toxicity\"]], \"start\": [[83], [94], [129], [151]], \"entity_id\": [\"T14\", \"T15\", \"T16\", \"T17\"]}}, \"Treatment\": {\"text\": [[\"5-FU\"]], \"start\": [[32]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[32]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"colon cancer\"]], \"start\": [[42]], \"entity_id\": [\"T19\"]}}}"
}
]
}
] |
110153_1 | There have been many reports of probable lithium-induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"lithium\", \"when serum lithium levels are within or close to the therapeutic range\"]], \"start\": [[41, 91]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"organic brain syndromes\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[32]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
16623611_3 | The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, olanzapine was discontinued because of weight gain and uncontrolled diabetes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"because\"]], \"start\": [[135]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"olanzapine was discontinued\"]], \"start\": [[107]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[107]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"weight gain and uncontrolled diabetes\"]], \"start\": [[146]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
4004433_4 | While most physicians are aware of heparin-induced thrombocytopenia and skin necrosis, the association of heparin and hyperkalemia is less well recognized. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[35]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[35]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia and skin necrosis\"]], \"start\": [[51]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16176119_2 | Gefitinib (IRESSA, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has been approved in several countries for the treatment of advanced non-small-cell lung cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[138]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Gefitinib\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"advanced non-small-cell lung cancer\"]], \"start\": [[151]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"Gefitinib\"], [\"IRESSA\"], [\"ZD1839\"], [\"epidermal growth factor receptor tyrosine kinase inhibitor\"]], \"start\": [[0], [11], [19], [31]], \"entity_id\": [\"T10\", \"T11\", \"T12\", \"T13\"]}}}"
}
]
}
] |
19520277_2 | The case of a 4-year-old girl with valproate-induced stupor and electroencephalographic pattern of increased fast activity is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[45]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[35]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"stupor and electroencephalographic pattern of increased fast activity\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 4-year-old girl\"]], \"start\": [[12]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"4-year-old\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16421117_2 | Prior to surgery, levodopa induced dyskinesia had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improved\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"treatment with amantadine (400 mg/day, po)\"]], \"start\": [[78]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"400 mg/day\"]], \"start\": [[105]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"all three patients\"]], \"start\": [[124]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[128]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"levodopa induced dyskinesia\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
8384030_3 | Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Foscarnet\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Foscarnet\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hypomagnesemia and other electrolyte disorders\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[18]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
667809_1 | A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"child with fatal pulmonary fibrosis\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"fatal pulmonary fibrosis\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"BCNU therapy\"]], \"start\": [[70]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"BCNU\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[35]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
15729090_3 | A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 64-year-old man with schizophrenia\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"64-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"myoclonic jerks\"]], \"start\": [[47]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"higher doses of quetiapine\"]], \"start\": [[74]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"schizophrenia\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"quetiapine\"]], \"start\": [[90]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"higher doses\"]], \"start\": [[74]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
15494638_18 | The etiology of neurotoxicity in our two patients remains unclear; however, as CAP is rapidly metabolized to 5-FU in patients with normal liver function, it is likely that 5-FU or its active metabolites (fluoro-beta-alanine) were contributing factors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"contributing\"]], \"start\": [[230]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[37]], \"entity_id\": [\"T10\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[37]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"5-FU or its active metabolites (fluoro-beta-alanine)\"]], \"start\": [[172]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"5-FU\"], [\"fluoro-beta-alanine\"]], \"start\": [[172], [204]], \"entity_id\": [\"T15\", \"T16\"]}}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[16]], \"entity_id\": [\"T13\"]}, \"Speculated\": {\"text\": [[\"it is likely\"]], \"start\": [[154]], \"entity_id\": [\"T17\"], \"value\": true}}"
}
]
}
] |
19034138_2 | CONCLUSIONS: Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Amantadine\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Amantadine\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"reversible corneal edema\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"irreversibly\"]], \"start\": [[67]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
1635565_1 | After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[71]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"several infants\"]], \"start\": [[51]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"infants\"]], \"start\": [[59]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"prostaglandin E1\"]], \"start\": [[80]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"prostaglandin E1\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"gastric-outlet obstruction\"]], \"start\": [[6]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10981493_2 | A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[79]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"propafenone\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"propafenone\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"adverse central nervous system effects\", \"dizziness\"]], \"start\": [[18, 109]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"most common\"]], \"start\": [[126]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
21712512_10 | Iatrogenic Cushing syndrome has been reported in patients with CF treated concomitantly, and for extended duration, with inhaled corticosteroids and CYP3A4 inhibitors. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[37]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"inhaled corticosteroids and CYP3A4 inhibitors\"]], \"start\": [[121]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"inhaled\"]], \"start\": [[121]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"CYP3A4 inhibitors\"]], \"start\": [[129], [149]], \"entity_id\": [\"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[145]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"CYP3A4 inhibitors\"]], \"start\": [[129], [149]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"Iatrogenic Cushing syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patients with CF\"]], \"start\": [[49]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"CF\"]], \"start\": [[63]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
17671884_1 | Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"Red blood cell anemia\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with pemphigus vulgaris\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"mycophenolate mofetil and prednisone\"]], \"start\": [[81]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"pemphigus vulgaris\"]], \"start\": [[40]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"mycophenolate mofetil\"], [\"prednisone\"]], \"start\": [[81], [107]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[103]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"mycophenolate mofetil\"], [\"prednisone\"]], \"start\": [[81], [107]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
1765991_1 | Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[42]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"interferon-gamma\"]], \"start\": [[45]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"interferon-gamma\"]], \"start\": [[45]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis.\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"systemic lupus erythematosus\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16997047_2 | In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"switching from citalopram to mirtazapine\"]], \"start\": [[85]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"citalopram\"], [\"mirtazapine\"]], \"start\": [[100], [114]], \"entity_id\": [\"T7\", \"T8\"]}, \"Time_elapsed\": {\"text\": [[\"5 months\"]], \"start\": [[70]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16945058_2 | This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"acute compromise of renal function\", \"hypotension\"]], \"start\": [[32, 83]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a 7-year-old boy\"]], \"start\": [[98]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"7-year-old\"]], \"start\": [[100]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[111]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"ACE inhibitor lisinopril and the ARB losartan\"]], \"start\": [[132]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lisinopril\"], [\"losartan\"]], \"start\": [[146], [169]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[157]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"lisinopril\"], [\"losartan\"]], \"start\": [[146], [169]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
9302445_4 | We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a male patient with advanced AIDS\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"male\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypercalcemia\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"2 weeks after institution of rhGH therapy\"]], \"start\": [[72]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"advanced AIDS\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"rhGH\"]], \"start\": [[101]], \"entity_id\": [\"T10\"]}, \"Time_elapsed\": {\"text\": [[\"2 weeks\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
1592841_2 | RESULTS: Both patients experienced a previously unreported side effect--falling backward--associated with bupropion use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[90]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"bupropion\"]], \"start\": [[106]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bupropion\"]], \"start\": [[106]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"Both patients\"]], \"start\": [[9]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Both\"]], \"start\": [[9]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"falling backward\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
150825_2 | A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"jaundice\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"intravaginal administration of a mixture of furazolidone and nifuroxime\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"furazolidone\"], [\"nifuroxime\"]], \"start\": [[86], [103]], \"entity_id\": [\"T7\", \"T8\"]}, \"Route\": {\"text\": [[\"intravaginal\"]], \"start\": [[42]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"mixture\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"furazolidone\"], [\"nifuroxime\"]], \"start\": [[86], [103]], \"entity_id\": [\"T7\", \"T8\"]}}]}}"
}
]
}
] |
18294121_2 | Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[76]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"an erythematous and exfoliative rash\"]], \"start\": [[32]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"temozolomide\"]], \"start\": [[87]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"temozolomide\"]], \"start\": [[87]], \"entity_id\": [\"T6\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
8255797_1 | Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Captopril\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Captopril\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"bone marrow suppression\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two cardiac patients with trisomy 21\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"cardiac\"], [\"trisomy 21\"]], \"start\": [[49], [71]], \"entity_id\": [\"T7\", \"T1\"]}}}"
}
]
}
] |
9796135_1 | A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate (5 mg). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sublingual ingestion of isosorbide dinitrate (5 mg)\"]], \"start\": [[70]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"angina pectoris\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"sublingual ingestion\"]], \"start\": [[70]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"isosorbide dinitrate\"]], \"start\": [[94]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"5 mg\"]], \"start\": [[116]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"syncope\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 65-year-old woman with angina pectoris\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1860779_1 | The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, obsessional-like suicidal ideas and images after ingestion of the anti-fungal drug ketoconazole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[74]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a mentally healthy man\"]], \"start\": [[36]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"man\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"short-lived, obsessional-like suicidal ideas and images\"]], \"start\": [[86]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ingestion of the anti-fungal drug ketoconazole\"]], \"start\": [[148]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[148]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"ketoconazole\"]], \"start\": [[182]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1356045_2 | Flaccid quadriparesis was noted after discontinuation of vecuronium. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"noted\"]], \"start\": [[26]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Flaccid quadriparesis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vecuronium\"]], \"start\": [[57]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"vecuronium\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17444802_2 | AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effects\"]], \"start\": [[73]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure\"]], \"start\": [[140]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"topical interferon (INF) alpha 2-beta\"]], \"start\": [[89]], \"entity_id\": [\"T8\"], \"Route\": {\"text\": [[\"topical\"]], \"start\": [[89]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"interferon\", \"alpha 2-beta\"]], \"start\": [[97, 114]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"conjunctiva-cornea intraepithelial neoplasia\"]], \"start\": [[140]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"tumor side effects\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
17044380_1 | Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"skin necrosis\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[92]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[84]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[84]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia\"]], \"start\": [[100]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
17026827_2 | We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"severe unilateral posterior scleritis\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"zoledronic acid\"]], \"start\": [[75]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"zoledronic acid\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19567656_5 | The patient's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause rhabdomyolysis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[124]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sertraline\"]], \"start\": [[104]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sertraline\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[130]], \"entity_id\": [\"T5\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"value\": true}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[77]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
11030530_1 | L-asparaginase-provoked seizures as singular expression of central nervous toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoked\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"seizures as singular expression of central nervous toxicity\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"L-asparaginase\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7351000_1 | Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute non-lymphocytic leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patients with ovarian carcinoma\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term treatment with Treosulfan (= dihydroxybusulfan)\"]], \"start\": [[76]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Treosulfan\"]], \"start\": [[101]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"ovarian carcinoma\"]], \"start\": [[48]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15694139_7 | Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"detect\"]], \"start\": [[94]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"Children\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"Children\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"thalidomide\"]], \"start\": [[22]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"thalidomide\"]], \"start\": [[22]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"presymptomatic or progressive peripheral neuropathy\"]], \"start\": [[101]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
11174414_2 | Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[131]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Nevirapine\"], [\"other antiretroviral agents\"]], \"start\": [[0], [95]], \"entity_id\": [\"T9\", \"T11\"]}, \"Disorder\": {\"text\": [[\"HIV infection\"]], \"start\": [[144]], \"entity_id\": [\"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"Nevirapine\"], [\"other antiretroviral agents\"]], \"start\": [[0], [95]], \"entity_id\": [\"T9\", \"T11\"]}}]}}"
}
]
}
] |
17260498_4 | The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 docetaxel who developed subacute interstitial pneumonitis-related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[135]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"weekly administration of 30 mg/m2 docetaxel\", \"seven doses\", \"despite mechanical ventilation and high-dose corticosteroid treatment\"]], \"start\": [[87, 212, 233]], \"entity_id\": [\"T14\"], \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[87]], \"entity_id\": [\"T19\"]}, \"Route\": {\"text\": [[\"administration\"]], \"start\": [[94]], \"entity_id\": [\"T20\"]}, \"Dosage\": {\"text\": [[\"30 mg/m2\"], [\"seven doses\"], [\"high-dose\"]], \"start\": [[112], [212], [268]], \"entity_id\": [\"T21\", \"T23\", \"T30\"]}, \"Drug\": {\"text\": [[\"docetaxel\"], [\"corticosteroid\"]], \"start\": [[121], [278]], \"entity_id\": [\"T22\", \"T24\"]}, \"Disorder\": {\"text\": [[\"hormone-refractory prostate cancer\"]], \"start\": [[48]], \"entity_id\": [\"T25\"]}}, \"Effect\": {\"text\": [[\"subacute interstitial pneumonitis-related pulmonary fibrosis\", \"and died\"]], \"start\": [[145, 224]], \"entity_id\": [\"T16\"]}, \"Subject\": {\"text\": [[\"a 72-year-old man with hormone-refractory prostate cancer\"]], \"start\": [[25]], \"entity_id\": [\"T12\"], \"Age\": {\"text\": [[\"72-year-old\"]], \"start\": [[27]], \"entity_id\": [\"T17\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[39]], \"entity_id\": [\"T18\"]}}, \"Severity\": {\"text\": [[\"died\"]], \"start\": [[228]], \"entity_id\": [\"T27\"], \"value\": \"Medium\"}}"
}
]
}
] |
10732843_5 | In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"promoted\"]], \"start\": [[137]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"low-dose methotrexate therapy\"]], \"start\": [[96]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[105]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"the development of lung cancer\"]], \"start\": [[146]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"pulmonary fibrosis\"]], \"start\": [[72]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"pulmonary fibrosis\"]], \"start\": [[72]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
21712512_1 | Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"onset\"]], \"start\": [[6]], \"entity_id\": [\"T14\"]}, \"Effect\": {\"text\": [[\"iatrogenic adrenal insufficiency\"]], \"start\": [[15]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"inhaled corticosteroids and a moderate CYP3A4 inhibitor\"]], \"start\": [[117]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"inhaled corticosteroids\"], [\"CYP3A4 inhibitor.\"]], \"start\": [[117], [156]], \"entity_id\": [\"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[141]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"inhaled corticosteroids\"], [\"CYP3A4 inhibitor.\"]], \"start\": [[117], [156]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Subject\": {\"text\": [[\"a patient with cystic fibrosis-related liver disease\"]], \"start\": [[51]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"cystic fibrosis-related liver disease\"]], \"start\": [[66]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
1722991_2 | Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[8]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Heparin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Heparin\"], [\"heparin\"]], \"start\": [[0], [88]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Effect\": {\"text\": [[\"thrombocytopenia and thrombosis\"]], \"start\": [[19]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
10891991_7 | The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"disappeared\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"polycystic changes disappeared from the ovaries\", \"lost weight and resumed menstruating\"]], \"start\": [[4, 210]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"2 of the women\"]], \"start\": [[55]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[55]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[64]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"after valproate therapy was discontinued\"]], \"start\": [[70]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[76]], \"entity_id\": [\"T14\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"while\"]], \"start\": [[175]], \"entity_id\": [\"T21\"]}, \"Subject\": {\"text\": [[\"2 women\"]], \"start\": [[120]], \"entity_id\": [\"T15\"], \"Population\": {\"text\": [[\"2\"]], \"start\": [[120]], \"entity_id\": [\"T19\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[122]], \"entity_id\": [\"T20\"]}}, \"Effect\": {\"text\": [[\"gained weight and developed amenorrhea\"]], \"start\": [[136]], \"entity_id\": [\"T18\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[200]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[200]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
11225532_2 | The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chronic ingestion of quinine\"]], \"start\": [[70]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[78]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"quinine\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thrombocytopoaenia\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[32]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
16882112_3 | The concomitant use of antidepressant drugs associated with lithium as a co-adjuvant seems to increase the risk of this adverse reaction. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increase\"]], \"start\": [[94]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"concomitant use of antidepressant drugs associated with lithium as a co-adjuvant\"]], \"start\": [[4]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"antidepressant drugs\"], [\"lithium\"]], \"start\": [[23], [60]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"antidepressant drugs\"], [\"lithium\"]], \"start\": [[23], [60]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"adverse reaction\"]], \"start\": [[120]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
2554727_3 | Peripheral nervous system disturbances caused by cytosine arabinoside have rarely been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Peripheral nervous system disturbances\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9315405_1 | We report an unusually short lived and asymptomatic episode of severe cisplatin-induced renal tubular salt wasting in a fit 41-year-old patient with malignant teratoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a fit 41-year-old patient with malignant teratoma\"]], \"start\": [[118]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"41-year-old\"]], \"start\": [[124]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"cisplatin\"]], \"start\": [[70]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"malignant teratoma\"]], \"start\": [[149]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[70]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"renal tubular salt wasting\"]], \"start\": [[88]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10102531_1 | This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[115]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine)\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"BH-AC\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"reversible encephalopathy syndrome\"]], \"start\": [[124]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"This case\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"could be\"]], \"start\": [[104]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
11816261_5 | She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[75]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"metoclopramide\"]], \"start\": [[21]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[21]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"nausea\"]], \"start\": [[47]], \"entity_id\": [\"T14\"]}, \"Time_elapsed\": {\"text\": [[\"within 2 hours\"]], \"start\": [[59]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"agitation, dysarthria, diaphoresis, and a movement disorder\"]], \"start\": [[85]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
448845_4 | This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"aplastic anemia\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methazolamide\"]], \"start\": [[118]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"methazolamide\"]], \"start\": [[118]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"almost certainly\"]], \"start\": [[79]], \"entity_id\": [\"T14\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[165]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"agranulocytosis\"]], \"start\": [[149]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"methazolamide\"]], \"start\": [[187]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"methazolamide\"]], \"start\": [[187]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
12584153_3 | Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treat\"]], \"start\": [[97]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Amprenavir\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"HIV-infected\"]], \"start\": [[103]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"Amprenavir\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"children\"]], \"start\": [[116]], \"entity_id\": [\"T11\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[116]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
18094347_4 | Methotrexate-induced papular eruption following treatment of psoriasis has not been previously reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Methotrexate\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"papular eruption\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19733945_2 | On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[45]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"linezolid\"]], \"start\": [[12]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[12]], \"entity_id\": [\"T17\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[33]], \"entity_id\": [\"T14\"]}, \"Effect\": {\"text\": [[\"pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level\", \"hepatitis\"]], \"start\": [[62, 166]], \"entity_id\": [\"T15\"]}, \"Severity\": {\"text\": [[\"severe\"], [\"mild\"]], \"start\": [[55], [161]], \"entity_id\": [\"T18\", \"T19\"], \"value\": \"Medium\"}}"
}
]
}
] |
8181372_2 | We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated with\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute interstitial pneumonitis\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient\", \"for a brain tumor\"]], \"start\": [[60, 101]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carmustine (BCNU)\"]], \"start\": [[83]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"carmustine (BCNU)\"]], \"start\": [[83]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"a brain tumor\"]], \"start\": [[105]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[12]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
10749332_4 | The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead\"]], \"start\": [[96]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"three reported cases\"]], \"start\": [[4]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"irreversible liver injury\"]], \"start\": [[104]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"troglitazone\"]], \"start\": [[42]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"troglitazone\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"irreversible\"]], \"start\": [[104]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
7814182_1 | High-grade atrioventricular block during dipyridamole stress testing. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"dipyridamole stress testing\"]], \"start\": [[41]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dipyridamole\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"High-grade atrioventricular block\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16453964_1 | We describe a case of intraoperative gelatine-induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intraoperative gelatine\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gelatine\"]], \"start\": [[37]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intraoperative\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"anaphylaxis\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
2406680_3 | The case of a 29-year-old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"got\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a 29-year-old man suffering from falciparum malaria disease\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"29-year-old\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"reversible hearing loss\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"quinine\"]], \"start\": [[111]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"falciparum malaria disease\"]], \"start\": [[45]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"quinine\"]], \"start\": [[111]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"reversible\"]], \"start\": [[82]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
7893301_3 | The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"two asthmatic patients\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypokalemic\"]], \"start\": [[47]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"inhalation of normal doses of albutero\"]], \"start\": [[65]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"asthmatic\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"inhalation\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"normal doses\"]], \"start\": [[79]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"albuterol\"]], \"start\": [[95]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
19537383_4 | This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated with\"]], \"start\": [[127]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sorafenib therapy\"]], \"start\": [[143]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sorafenib\"]], \"start\": [[143]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"an atypical localized cutaneous eruption with an unusual course and protracted resolution time\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16480245_1 | METHOD: We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively. | false | [
{
"events": [
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[37]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"quetiapine and risperidone\"]], \"start\": [[95]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"quetiapine\"], [\"risperidone\"]], \"start\": [[95], [110]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Effect\": {\"text\": [[\"diabetic ketoacidosis\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9855339_4 | We suspect that nefazodone inhibits metabolism of tacrolimus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"inhibits\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nefazodone\"]], \"start\": [[16]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"nefazodone\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"metabolism of tacrolimus\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"suspect\"]], \"start\": [[3]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
9184269_4 | Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX-induced pneumonitis, giving a prevalence of 2.1% and 0.03%, respectively. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[125]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[121]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"RA\"], [\"PsA\"]], \"start\": [[84], [104]], \"entity_id\": [\"T12\", \"T13\"]}, \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[121]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[133]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient\"]], \"start\": [[14]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"four\"], [\"one\"]], \"start\": [[79], [100]], \"entity_id\": [\"T7\", \"T8\"]}}}"
}
]
}
] |
12862258_1 | A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"agranulocytosis\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an Indian mid-borderline leprosy patient\"]], \"start\": [[58]], \"entity_id\": [\"T6\"], \"Race\": {\"text\": [[\"Indian\"]], \"start\": [[61]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"mid-borderline leprosy\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[17]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
16498048_1 | Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side-effect\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Autoimmune thyroid disease\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"interferon-alpha (IFN-alpha)\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"interferon-alpha\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"viral hepatitis C\"]], \"start\": [[96]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15866658_4 | The side effects of MMF, such as bone marrow toxicity, have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"MMF\"]], \"start\": [[20]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"MMF\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"bone marrow toxicity\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
15727358_1 | He developed a late secondary infection in some sites treated with imiquimod. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[3]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"late secondary infection\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"imiquimod\"]], \"start\": [[67]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"imiquimod\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19104709_3 | We report the case of a 51-year-old man in whom IFN-alpha treatment was followed by recurrence of Graves' disease 10 years after thyroidectomy was performed and the patient was declared cured. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 51-year-old man\"]], \"start\": [[22]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"51-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"IFN-alpha treatment\", \"10 years after thyroidectomy\"]], \"start\": [[48, 114]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"recurrence of Graves' disease\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9407188_2 | We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of ritonavir, a protease inhibitor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"infected\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"ritonavir\"]], \"start\": [[157]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"human immunodeficiency virus\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"ritonavir\"]], \"start\": [[157]], \"entity_id\": [\"T14\"]}, \"Time_elapsed\": {\"text\": [[\"2nd day of first administration\"]], \"start\": [[122]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"maculopapular eruption and fever\"]], \"start\": [[21]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[57]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
18344734_2 | We report the case of a woman who developed photo-onycholysis on multiple nails after uptake of olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[22]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"photo-onycholysis on multiple nails\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"uptake of olanzapine\"]], \"start\": [[86]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"after uptake\"]], \"start\": [[80]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
6733633_2 | Cimetidine is a rare cause of drug-induced fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Cimetidine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Cimetidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19745701_2 | Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[11]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[11]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"lymphoproliferative disorder\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11077455_5 | The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"persist\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"field defects and some electrophysiological abnormalities persist\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vigabatrin therapy is withdrawn\"]], \"start\": [[75]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"vigabatrin\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9177620_1 | A possible case of carbamazepine induced pancreatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[19]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pancreatitis\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A possible case\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[2]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
24791374_4 | Subsequent to the first dose of mirtazapine the patient experienced seizures, bradycardia and prolonged QRS as well as QTc intervals on EKG. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Subsequent\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"mirtazapine\"]], \"start\": [[32]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"mirtazapine\"]], \"start\": [[32]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[44]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"seizures, bradycardia and prolonged QRS as well as QTc intervals on EKG\"]], \"start\": [[68]], \"entity_id\": [\"T12\"]}}"
}
]
}
] |
18665833_1 | Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with protein C deficiency\"]], \"start\": [[53]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Stuttering priapism\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"protein C deficiency\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[33]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12187348_6 | She had been on a combined treatment of steroid and lobenzarit disodium for the first 3 years, and then continued with a combined treatment of steroid and bucillamine for the following years until she was found to have pulmonary tuberculosis, at which time the steroid was suspended 10 months before she visited the authors' clinic. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[27]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"pulmonary tuberculosis\"]], \"start\": [[219]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"steroid and lobenzarit disodium for the first 3 years, and then continued with a combined treatment of steroid and bucillamine for the following years\"]], \"start\": [[40]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"steroid\"], [\"bucillamine\"], [\"lobenzarit disodium\"], [\"steroid\"]], \"start\": [[143], [155], [52], [40]], \"entity_id\": [\"T13\", \"T16\", \"T17\", \"T18\"]}, \"Time_elapsed\": {\"text\": [[\"3 years\"]], \"start\": [[86]], \"entity_id\": [\"T20\"]}, \"Duration\": {\"text\": [[\"for the following years\"]], \"start\": [[167]], \"entity_id\": [\"T21\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[121]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"steroid\"], [\"bucillamine\"], [\"lobenzarit disodium\"], [\"steroid\"]], \"start\": [[143], [155], [52], [40]], \"entity_id\": [\"T13\", \"T16\", \"T17\", \"T18\"]}}]}}"
}
]
}
] |
24791374_2 | We describe a rare case of severe drug-drug interaction between propafenone and mirtazapine leading to propafenone toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"leading\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a rare case\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"propafenone and mirtazapine\"]], \"start\": [[64]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"propafenone\"], [\"mirtazapine\"]], \"start\": [[64], [80]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"propafenone\"], [\"mirtazapine\"]], \"start\": [[64], [80]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"propafenone toxicity\"]], \"start\": [[103]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[27]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
9512187_1 | Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoking\"]], \"start\": [[168]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"acral necrosis\", \"Raynaud's phenomenon\"]], \"start\": [[178, 217]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"bleomycin\", \"vinca alkaloids\"]], \"start\": [[27, 41]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bleomycin\"], [\"vinca alkaloids\"]], \"start\": [[27], [41]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[37]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"bleomycin\"], [\"vinca alkaloids\"]], \"start\": [[27], [41]], \"entity_id\": [\"T8\", \"T9\"]}}]}}"
}
]
}
] |
12875956_3 | The psychotic behavior resolved completely soon after the discontinuation of levetiracetam. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"discontinuation of levetiracetam\"]], \"start\": [[58]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"psychotic behavior\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Time_elapsed\": {\"text\": [[\"soon after\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"levetiracetam\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15034704_3 | Male volunteers ( n=12) participated in a randomised, two-period, crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[165]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Male volunteers ( n=12)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Gender\": {\"text\": [[\"Male\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Population\": {\"text\": [[\"n=12\"]], \"start\": [[18]], \"entity_id\": [\"T12\"]}}, \"Treatment\": {\"text\": [[\"multiple doses of 600 mg rifampicin once daily for 7 days\"]], \"start\": [[107]], \"entity_id\": [\"T8\"], \"Dosage\": {\"text\": [[\"multiple doses of 600 mg\"]], \"start\": [[107]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[132]], \"entity_id\": [\"T14\"]}, \"Freq\": {\"text\": [[\"once daily\"]], \"start\": [[143]], \"entity_id\": [\"T15\"]}, \"Duration\": {\"text\": [[\"7 days\"]], \"start\": [[158]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"repaglinide metabolism\"]], \"start\": [[168]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
17671884_9 | This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[43]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"anemia\"]], \"start\": [[26]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"MMF\", \"prednisone\"]], \"start\": [[50, 91]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"MMF\"], [\"prednisone\"]], \"start\": [[50], [91]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[86]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"MMF\"], [\"prednisone\"]], \"start\": [[50], [91]], \"entity_id\": [\"T18\", \"T19\"]}}]}, \"Speculated\": {\"text\": [[\"can\"]], \"start\": [[33]], \"entity_id\": [\"T17\"], \"value\": true}}"
}
]
}
] |